Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Daily Archives: January 14, 2020

$700K R&D Tax Incentive Refund.

News & Announcements 2020By PharmAustJanuary 14, 2020

200114_$700K R&D Tax Incentive Refund

MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube
TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
Retweet on Twitter PharmAust Retweeted
pharmaust PharmAust @pharmaust ·
30 Mar

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 3 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360
Retweet on Twitter PharmAust Retweeted
pharmaust PharmAust @pharmaust ·
30 Mar

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 5 Like on Twitter 1641272193236758529 17 Twitter 1641272193236758529
pharmaust PharmAust @pharmaust ·
11h

MND trial completes enrolment of 'Cohort 2' and prepares for interim analysis
Via @BiotechDispatch
https://biotechdispatch.com.au/news/mnd-trial-completes-enrolment-of-cohort-2-and-prepares-for-inter

Reply on Twitter 1641571161678151680 Retweet on Twitter 1641571161678151680 2 Like on Twitter 1641571161678151680 9 Twitter 1641571161678151680
Load More
Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top